Kusters Miranda, Slater Andrew, Muirhead Rebecca, Hompes Roel, Guy Richard J, Jones Oliver M, George Bruce D, Lindsey Ian, Mortensen Neil J, Cunningham Chris
1 Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands 2 Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands 3 Department of Radiology, Oxford University Hospitals NHS Foundation Trust, United Kingdom 4 CRUK MRC Oxford Institute for Radiation Oncology, Oxford University Hospitals NHS Foundation Trust, United Kingdom 5 Department of Colorectal Surgery, Oxford University Hospitals NHS Foundation Trust, United Kingdom.
Dis Colon Rectum. 2017 Jun;60(6):577-585. doi: 10.1097/DCR.0000000000000834.
There remains a lack of international consensus on the appropriate management of lateral nodal disease. Although the East manages this more aggressively with lateral lymph node dissections, the West aims to eradicate small-volume disease with neoadjuvant chemoradiotherapy and lateral nodal disease is not considered for routine surgical treatment. However, recent studies have shown that, despite neoadjuvant treatment, a significant number of patients with lateral nodal disease develop local recurrence in the lateral compartment after total mesorectal excision.
The aim of this study is to assess the role of the pretreatment features of lateral nodes on MRI in regard to local recurrence.
All patients operated on for low locally advanced rectal cancer over a 5-year period were evaluated retrospectively.
This study was conducted at a single expert center.
The MRIs of a total of 313 patients were reviewed, and only those with rectal cancers up to 8 cm from the anorectal junction, measured on MRI, were selected. This left 185 patients; of these, 58 patients had clinical T1 or T2 tumors as assessed on MRI, identifying 127 patients who had cT3/T4 tumors that were included in this study.
The primary outcomes measured were lateral local recurrence and multivariate analyses.
The lateral local recurrence rate was significantly higher (33.3% 4-year rate) in patients with nodes larger than 10 mm than in patients with smaller nodes (10.1%, p = 0.03), despite patients being irradiated in the lateral compartment.
Because this is a relatively uncommon disease, patient numbers are low, and a multicenter study is needed to further address lateral nodal disease in low rectal cancer.
Chemoradiotherapy with total mesorectal excision might not be sufficient in a selected group of patients. Further research is needed about which pretreatment features of the lateral nodes predict local recurrence and what is needed to prevent these from developing. See Video Abstract at http://links.lww.com/DCR/A338.
对于侧方淋巴结疾病的恰当管理,目前国际上仍未达成共识。尽管东方通过侧方淋巴结清扫术对此进行更积极的处理,但西方旨在通过新辅助放化疗根除小体积疾病,且侧方淋巴结疾病不被视为常规手术治疗的对象。然而,最近的研究表明,尽管进行了新辅助治疗,但相当数量的侧方淋巴结疾病患者在全直肠系膜切除术后侧方区域出现局部复发。
本研究旨在评估磁共振成像(MRI)上侧方淋巴结的预处理特征对局部复发的作用。
对5年内接受低位局部进展期直肠癌手术的所有患者进行回顾性评估。
本研究在一个单一的专家中心进行。
共回顾了313例患者的MRI,仅选择MRI测量显示距肛门直肠交界8厘米以内的直肠癌患者。最终留下185例患者;其中,58例患者经MRI评估为临床T1或T2肿瘤,确定127例cT3/T4肿瘤患者纳入本研究。
测量的主要结果是侧方局部复发和多变量分析。
尽管患者接受了侧方区域的放疗,但淋巴结大于10毫米的患者侧方局部复发率(4年率为33.3%)显著高于淋巴结较小的患者(10.1%,p = 0.03)。
由于这是一种相对罕见的疾病,患者数量较少,需要进行多中心研究以进一步探讨低位直肠癌的侧方淋巴结疾病。
对于特定患者群体,全直肠系膜切除联合放化疗可能并不足够。需要进一步研究侧方淋巴结的哪些预处理特征可预测局部复发以及预防其发生需要采取什么措施。见视频摘要:http://links.lww.com/DCR/A338 。